| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.22▼ | 4.22▼ | 4.35▼ | 4.36▼ | 4.56▼ |
| MA10 | 4.47▼ | 4.47▼ | 4.53▼ | 4.42▼ | 4.70▼ |
| MA20 | 4.58▼ | 4.62▼ | 4.68▼ | 4.58▼ | 4.84▼ |
| MA50 | 4.75▼ | 4.76▼ | 4.79▼ | 4.73▼ | 6.17▼ |
| MA100 | 4.80▼ | 4.83▼ | 4.82▼ | 4.91▼ | 4.33▼ |
| MA200 | 4.93▼ | 5.20▼ | 5.49▼ | 5.97▼ | 4.00▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.075▼ | -0.079▼ | -0.078▼ | -0.039▼ | -0.029▼ |
| RSI | 28.112▼ | 27.779▼ | 30.368▼ | 33.144▼ | 34.314▼ |
| STOCH | 9.524▼ | 9.524▼ | 30.895 | 26.400 | 31.762 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -83.341▼ | -88.741▼ |
| CCI | -159.339▼ | -159.793▼ | -202.404▼ | -225.847▼ | -246.037▼ |
|
Thursday, December 04, 2025 05:47 AM
Savara (NASDAQ:SVRA) advances rare-disease respiratory programs while remaining part of biotechnology themes tied to nasdaq today.
|
|
Thursday, December 04, 2025 04:51 AM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
|
|
Wednesday, December 03, 2025 01:09 PM
Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/12/25 | 4.28 | 4.28 | 3.9001 | 4.08 | 19,110 |
| 04/12/25 | 4.395 | 4.435 | 4.26 | 4.27 | 5,587 |
| 03/12/25 | 4.31 | 4.45 | 4.30 | 4.43 | 7,115 |
| 02/12/25 | 4.45 | 4.5815 | 4.3401 | 4.43 | 4,905 |
| 01/12/25 | 4.36 | 4.6669 | 4.36 | 4.57 | 8,531 |
| 28/11/25 | 4.61 | 4.61 | 4.37 | 4.45 | 8,561 |
| 26/11/25 | 4.6073 | 4.80 | 4.44 | 4.49 | 14,966 |
| 25/11/25 | 4.50 | 4.50 | 4.32 | 4.32 | 6,941 |
| 24/11/25 | 4.50 | 4.58 | 4.41 | 4.50 | 6,718 |
| 21/11/25 | 4.56 | 4.72 | 4.36 | 4.70 | 3,947 |
|
|
||||
|
|
||||
|
|